91 results about "Liver disorder" patented technology

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention belongs to the technical field of hepatopathy treatment drugs, and particularly relates to an anti-inflammatory and anti-oxidative stress nano-enzyme Cu5.4O atCNDs with cascade enzyme activity and application of the nano-enzyme Cu5.4O atCNDs. The nano-enzyme Cu5.4O-coated CNDs is prepared by the following steps: dissolving CuCl2 in a carbon dot aqueous solution, reacting for 10-12 minutes at the temperature of 75-80 DEG C, then adding an L-ascorbic acid aqueous solution, regulating the pH value to 7.0-8.0 by using a NaOH solution, reacting for 10-12 hours at the temperature of 75-80 DEG C, after the reaction is finished, centrifuging to remove precipitates, dialyzing supernate, and freeze-drying to obtain the Cu5.4O-coated CNDs. Research results of the invention prove that the nano-enzyme Cu5.4O-coated CNDs has the potential of treating various acute liver injury diseases, and is an intervention strategy with a good clinical application prospect.

Disclosed herein are oral compositions of small molecule GLP-1 agonists and GIP / GLP-1 dual receptor agonists and uses thereof.

The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK1 and MKK7. In formula (I), especially, Rw is —NR10SO2R12; either a) Rx and Ry are F and Rz and Rzz are H; or b) Rx, Ry and Rzz are independently halogen and Rz is H; R5 is substituted phenyl or pyrimidinyl.

Provided are an inhibitor containing a bicyclic derivative, a preparation method therefor and the use thereof. In particular, involved are a compound shown by general formula (I), a preparation method therefor, a pharmaceutical composition thereof, and the use thereof as an RET inhibitor in the treatment of cancers, inflammations, chronic liver diseases, diabetes, cardiovascular diseases, AIDS, and other related diseases, wherein each substituent in general formula (I) has the same definition as that given in the description.

Featured are methods of identifying (e.g., diagnosing) and / or treating a subject having or at risk of developing a liver disorder, such as liver steatosis, liver fibrosis, liver cirrhosis, and / or liver cancer (e.g., HCC). The methods utilize predictive and / or diagnostic biomarkers for identifying a subject as having or having a risk of a liver disorder. The predictive and / or diagnostic biomarkers described herein can also be used to monitor the status of a subject determined to have liver disorder or a risk thereof during treatment with a liver therapy. Also disclosed are methods of treating a subject determined to have a liver disorder (e.g., liver cancer, such as HCC) or a risk thereof (e.g., by assessing the level of one or more of the disclosed biomarkers by administering a liver therapy to the subject.

Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and / or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD, NASH, or MASH, or drug induced liver injury (DILI).

The application discloses a prognosis risk prediction model construction system and method based on chronic disease real world data, comprising a multi-source real world data acquisition and access module, a data standardization and quality control module, a multi-dimensional feature engineering and screening module, a comorbidity feature fusion and data set construction module, a prognosis risk prediction model training and optimization module, a model multi-dimensional verification and evaluation module, a model deployment and risk stratification output module; a special multi-source real world data acquisition and quality control system for chronic liver disease, diabetes and hypertension is constructed, data standardization processing is realized in combination with a chronic disease clinical diagnosis and treatment guideline, through multi-dimensional missing value, abnormal value processing and data deduplication integration, the quality and availability of the real world data are effectively improved, the core problem of disorderly and low-quality real world data in the prior art is solved, and a high-quality data source basis is provided for model construction.

The present disclosure is directed to a method of monitoring treatment of metabolic dysfunction-associated steatohepatitis (MASH) in a patient by initiating a treatment by administering Compound 1: (Compound 1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof to the patient, determining percentage increase in the level of SHBG from baseline, and continuing administration of Compound 1 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof to the patient if the percentage increase in the level of SHBG is at least 50% from baseline.

Small molecule GLP-1 receptor agonist compounds, pharmaceutical compositions, and their use and preparation are disclosed herein.

The application relates to the technical field of medical treatment and discloses a liver chronic disease screening method, a device and a storage medium.The method comprises the following steps: a liver detection system collects liver stiffness data and liver fat attenuation parameters of a target object; a mobile terminal system receives the liver stiffness data and the liver fat attenuation parameters, combines the liver stiffness data and the liver fat attenuation parameters with basic information of a preset target object, generates acquisition characteristic data, carries out label marking matrix processing on pretreatment integrated data of the cloud service system, generates a label marking matrix, carries out fitting residual processing on the label marking matrix, obtains extended decision tree data, carries out discrete sampling processing on the extended decision tree data, obtains a sparse vector, carries out classification calculation processing on the sparse vector, obtains a classification result, and generates a disease screening report based on the classification result.In the embodiment of the application, through system architecture and cloud service system data processing, the early warning timeliness and accuracy of liver chronic disease screening are improved.

Disclosed herein are oral compositions of small molecule GLP-1 agonists and GIP / GLP-1 dual receptor agonists and uses thereof.

Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize treatment with a THR-β agonist.

The invention discloses compounds of Formula (I), wherein the compounds are used as anti-inflammatory agents, for treatment or prevention of a number of diseases or conditions such as atherosclerosis, auto-immune diseases, psoriasis, multiple sclerosis, transplant rejection, asthma, bacterial infection, rhinovirus infection, brain ischemia, ischemia-reperfusion injury, limb ischemia, acute kidney injury, diabetic nephropathy, sepsis, acute respiratory distress syndrome (ARDS), cancer, osteoarthritis, sepsis-induced kidney injury, liver disease, and septic and cardiogenic shock.

The invention relates to the technical field of medical auxiliary instruments, and discloses an abdominal puncture auxiliary device for the hepatopathy department, the abdominal puncture auxiliary device comprises a supporting plate main body, the top of the supporting plate main body is slidably connected with a trunk fixing structure. According to the abdominal puncture auxiliary device for the hepatopathy department, a movable plate slidably connected to the top of the supporting plate body is matched with a limiting block and a threaded rod with a handle, so that a trunk is rapidly clamped by a first clamping plate, and the left-right position of the trunk is adjusted; a clamping block is driven by a buckle shell with a first spring and a pull rod to be connected with a plurality of clamping grooves in a supporting plate body in a clamped mode, accurate adjustment and locking of the overall position of the trunk fixing structure are achieved, and a multi-degree-of-freedom connecting rod mechanism is formed by sequentially hinging a first connecting rod, a second connecting rod and a third connecting rod and provided with a resistance pad at the hinged position; flexible hovering and positioning of the limbs of the patient are achieved, and automatic adaptation and elastic clamping of the upper limbs of the patient are achieved.

Disclosed herein are oral compositions of small molecule GLP-1 agonists and GIP / GLP-1 dual receptor agonists and uses thereof.

To provide methods and systems for assays that accurately determine lipoproteins in a plasma or serum sample and predict patient mortality, in contrast to conventional lipid panels incapable of detecting the presence of LP-X or LP-Z.SOLUTION: Described herein are methods for the determination of patient mortality from alcoholic hepatitis in biosamples by NMR spectroscopy, and more specifically, methods for the determination of a Z index score based on lipoprotein constituent LP-Z in blood plasma and serum.SELECTED DRAWING: Figure 4

This document describes bile acid derivatives, their manufacturing methods, and their uses. These derivatives have shown potential as therapeutic agents for the treatment of liver diseases.

The invention discloses an application of a traditional Chinese medicine composition in preparation of a medicine for preventing or treating acute and chronic liver diseases, and relates to the technical field of medicines, the application is the application of the traditional Chinese medicine composition in preparation of the medicine for preventing or treating acute and chronic liver diseases, and the traditional Chinese medicine composition is prepared from red ginseng, fructus aurantii and rabdosia amethystoides. Experiments find that the traditional Chinese medicine composition can significantly improve liver lipid accumulation, reduce the level of inflammatory factors of inflammatory cells and improve liver fibrosis indexes, and the effect is superior to that of a positive drug rosimeltirol; acute liver injury induced by ethanol is improved; the traditional Chinese medicine composition can improve the activity of LPL, enhance lipid metabolism and reduce blood fat, so that the effect of preventing or treating acute and chronic liver diseases is achieved, and the clinical application value of the traditional Chinese medicine composition is expanded.

Disclosed herein are small molecule GIP / GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

A lipid nanoparticle composition (LNP); a process for preparing LNP; the use of LNP includes, but is not limited to, methods for treating certain diseases and disorders, including, but is not limited to, liver disorders; kits for delivering nucleic acids in vivo, ex vivo, and in vitro to various types of cells, including T cells and hepatocytes.

Bile acid derivatives, methods of manufacture thereof, and uses thereof are disclosed herein. The bile acid derivatives have demonstrated potential as therapeutics for treating liver disease.

Disclosed are chimeric agonists of GCGR, GIPR, GLP-1R, and Y2R, and their use in the treatment of diseases and conditions such as diabetes, obesity, Alzheimer's disease, liver disease, substance addiction, traumatic brain injury, chronic kidney disease, inflammation and cardiovascular diseases.

Disclosed herein are small molecule GIP / GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

The present invention discloses a traditional Chinese medicine compound preparation for treating chronic liver disease, as well as its preparation method and application. The raw materials of the effective ingredients of the traditional Chinese medicine compound preparation include astragalus, raw oyster, polygonatum, seaweed, poria, salvia miltiorrhiza, zedoaria, raw turtle shell, kelp, phyllanthus urinaria, sophora flavescens, bupleurum, cyperus rotundus, vinegar-cured corydalis, and Panax notoginseng. The traditional Chinese medicine compound preparation of the present invention is mainly used for chronic liver disease and liver fibrosis, and is symptomatic. It has the effects of promoting blood circulation and removing blood stasis, removing dampness and resolving phlegm, softening and dispersing hard masses, and has good absorption effect, significant efficacy, no toxic side effects and clinical adverse reactions. It has a high cure rate for liver fibrosis as clinically verified.

The present invention relates to Bifidobacterium longum strain CECT 30763, to cellular components, metabolites and secreted molecules thereof, to compositions comprising the products mentioned above, and to their use in the prevention or treatment of mood disorders (e.g., depression and anxiety), cardiovascular metabolic disorders or liver disorders presented alone or as a co-disease.

Estimation of liver disease activity using ultrasound medical imaging. An ultrasound-based estimation (40) of disease activity is provided, such as an estimation of the NAS of NAFLD or other activity indices of liver disease. Ultrasound measurements (30, 32) are made of acoustic scattering and shear wave propagation parameters, such as measuring the acoustic backscatter coefficient, shear wave speed, and shear wave damping ratio. A score of disease activity is determined (40) from these scattering and shear wave propagation parameters. In scoring the activity of a disease such as NAFLD, a doctor can get the assistance of relatively inexpensive and rapid ultrasound. Ultrasound imaging (42) is more readily available and less expensive than MRI. Ultrasound is non-invasive.

The disclosure provides potent, selective and orally bioavailable inhibitors of nicotinamide N-methyltransferase (NNMT) which have a triazolone-piperidine scaffold. The NNMT inhibitors are useful for treating tumors and cancers, metabolic disorders and liver disorders.